Trends in 1-year persistence and adherence among initiators of high-potency, weight loss-indicated glucagon-like peptide 1 receptor agonists - PubMed
3 hours ago
- #Persistence Trends
- #Weight Loss
- #GLP-1RA
- Study examines 1-year persistence and adherence trends in high-potency GLP-1RAs (semaglutide and tirzepatide) for weight loss in non-diabetic individuals.
- Persistence rates increased from 33.2% in 2021 to 60.9% in the first half of 2024, nearly doubling over the period.
- Tirzepatide showed higher persistence rates (64.0% in 2023 and 64.8% in 1H 2024) compared to semaglutide.
- Factors potentially influencing improved persistence include resolution of GLP-1RA shortages, better dose escalation, side effect management, and lifestyle programs.
- Study highlights the need for further research on discontinuation reasons and long-term cost-effectiveness of GLP-1RAs.